While tumor growth in immunized B cell-deficient mice was comparable to controls and showed no detectable antibodies in their serum, treatment of mice with anti-HER2 serum prevented tumor growth in vivo as effectively as adenoviral vaccination, supporting the necessity and sufficiency of antibodies for anti-tumor protection (137). Here, ERBB2 is linked to neoplasm.